AstraZeneca’s Vaxzevria (AZD1222) Receives Approval for Emergency Use in Japan to Treat COVID-19
AstraZeneca’s Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia
Shots:
- MHLW has granted EUA for Vaxzevria (ChAdOx1-S [Recombinant]) for active immunization of individuals aged ≥18yrs. to prevent COVID-19. The EUA is based on P-III data from the Oxford University-led clinical trial in the UK, Brazil and South Africa, and a P-I/II trial in Japan
- PMDA recommends the use of Vaxzevria should be limited to adults & administered IM as two 0.5mL doses given 4-12 weeks apart, with an interval >8wks. The dosing regimen was well tolerated with no severe cases & no hospitalizations >14 days after the second dose
- Vaxzevria can be stored at 2-8 degrees Celsius for at least 6mos. The vaccine is expected to be available in the coming weeks
Click here to read full press release/ article | Ref: AstraZeneca | Image: The Scientist Magazine